What is Afamelanotide?
Afamelanotide is an alpha-MSH analogue investigated for photoprotection in erythropoietic protoporphyria (EPP). Melanotan I is a research name associated with this molecule; an implant trial does not verify a retail research vial.
Biological role or research focus
Erythropoietic protoporphyria photoprotection.
These findings are specific to EPP and the tested implants. They do not establish a safe cosmetic tanning regimen or interchangeability with Melanotan II.
Role reference: Afamelanotide for Erythropoietic Protoporphyria. · 2015 ↗
Names you may encounter
Melanotan I · Melanotan 1 · NDP-MSH
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Alpha-MSH analogue; Melanotan I research name
- Research focus
- Erythropoietic protoporphyria photoprotection
- Featured evidence
- Human randomized trials
- Source check
- October 4, 2026
Source: Afamelanotide for Erythropoietic Protoporphyria. · 2015 ↗
Quick answers
- Is Afamelanotide FDA approved?
- Yes. Scenesse implant (NDA 210797, approved October 2019) to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). Source ↗
- Is Afamelanotide safe?
- Approved drug for a rare light-sensitivity disorder (erythropoietic protoporphyria); the main concerns are allergic reactions and darkening of skin and moles. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Afamelanotide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Afamelanotide implants in erythropoietic protoporphyria (2015) | Human randomized trials | 74 participants in the European trial and 94 in the US trial, all with EPP. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trials · 2015
Afamelanotide implants in erythropoietic protoporphyria
What did this publication test, and what did it find?
- Population / model
- 74 participants in the European trial and 94 in the US trial, all with EPP.
- Study design
- Two randomized double-blind placebo-controlled implant trials.
- Main finding
- Pain-free sun exposure was longer with afamelanotide in both trials, and quality-of-life measures improved. Reported median exposure values differed considerably between the two study settings.
- Limits & context
- These findings are specific to EPP and the tested implants. They do not establish a safe cosmetic tanning regimen or interchangeability with Melanotan II.
Source: Afamelanotide for Erythropoietic Protoporphyria. · 2015 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
23 registered studies name Afamelanotide as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet, 18 completed and 4 ended early, were withdrawn or have another status. Checked November 14, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 23 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Vitiligo: Pathogenesis and New and Emerging Treatments. ↗
International journal of molecular sciences · 2023 Dec 9 · Journal Article, Review
Read available full text ↗
Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. ↗
International journal of molecular sciences · 2023 Mar 3 · Journal Article, Review
Read available full text ↗
Afamelanotide. ↗
· 2012 · Review
From pathogenesis of acne vulgaris to anti-acne agents. ↗
Archives of dermatological research · 2019 Jul · Journal Article, Review
Risks & interactions
Approved drug for a rare light-sensitivity disorder (erythropoietic protoporphyria); the main concerns are allergic reactions and darkening of skin and moles.
Safety comes from FDA-approved labeling (Scenesse) based on three controlled trials in about 244 adults with EPP who did not have significant liver involvement, plus postmarketing reports. The label has no drug interaction section, and long-term data are limited.
No condition tags: its FDA label does not single out these conditions. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
- People with a past severe allergic reaction to afamelanotide or any ingredient
Serious risks
- Serious allergic reactions, including anaphylaxis, reported after approval
- Generalized skin darkening and darkening of existing moles and freckles; the label recommends regular full-body skin exams
Common side effects
- implant-site reactions
- nausea
- sore throat
- cough
- fatigue
- skin darkening
- dizziness
- new or changed moles
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Scenesse (afamelanotide) prescribing information ↗
Safety & what remains unknown
Adverse events were generally mild in the reports. Complete product precautions and longer-term surveillance should be consulted for the exact medicine.
Source: Afamelanotide for Erythropoietic Protoporphyria. · 2015 ↗
Evidence boundaries
These findings are specific to EPP and the tested implants. They do not establish a safe cosmetic tanning regimen or interchangeability with Melanotan II.
Source: Afamelanotide for Erythropoietic Protoporphyria. · 2015 ↗
Official product context · checked October 4, 2026
The label describes pigment changes, skin surveillance, and hypersensitivity reactions. Maintaining light protection remains part of care. These precautions concern the approved implant, rather than an unverified research vial.
Source: DailyMed · Scenesse prescribing information ↗
Regulatory status
- U.S. FDA approval
- Approved
Scenesse implant (NDA 210797, approved October 2019) to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. It has government approval (FDA, 2019), so the S0 catch-all does not apply. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
The U.S. Scenesse label concerns adults with erythropoietic protoporphyria and phototoxic reactions. Its implant is intended to increase light exposure without pain; that indication does not extend to cosmetic tanning products.
The featured trials concern people with EPP and a defined implant preparation. Current product indications and availability require local prescribing references.
Source: DailyMed · Scenesse prescribing information ↗
Source: Afamelanotide for Erythropoietic Protoporphyria. · 2015 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Biology & proposed mechanism
Its melanocortin-related pigment signaling was evaluated through pain-free light exposure in EPP. That disease-specific outcome differs from cosmetic tanning.
Source: Afamelanotide for Erythropoietic Protoporphyria. · 2015 ↗
Questions worth asking
- Does the implant evidence apply to every Melanotan I vial?
- What material, population, and route were actually studied?
- These findings are specific to EPP and the tested implants. They do not establish a safe cosmetic tanning regimen or interchangeability with Melanotan II.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does the implant evidence apply to every Melanotan I vial?
No. A matching name does not verify composition, formulation, manufacturing, or equivalence to the studied implant.
Source: Afamelanotide for Erythropoietic Protoporphyria. · 2015 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: Afamelanotide for Erythropoietic Protoporphyria. · 2015 ↗
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Melanotan I vs Melanotan II: one became a medicine, one did not
Melanotan I and Melanotan II were developed in the same lab to darken skin, but only Melanotan I (afamelanotide) became an approved medicine, for a rare light-sensitivity disease. Melanotan II has only tiny early studies and documented safety concerns.
Read the guide →
